1. , , , et al. Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction. J Am Coll Surg 2009; 209: 198–205.
2. , , , et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma Acute Care Surg 2009; 66: 346–52.
3. , , , et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma Acute Care Surg 2008; 65: 755–64.
4. , , . Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006; 46: 685–6.
5. , , , et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma Acute Care Surg 2008; 65: 527–34.
6. , , , , . Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44: 809–13.
7. , , . Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma Acute Care Surg 2006; 60 (6 Suppl): S91–6.
8. , , , et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma Acute Care Surg 2007; 63: 805–13.
9. , , , et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447–58.
10. , , , et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma Acute Care Surg 2009; 66: 358–62.
11. , , , et al. Improved survival after hemostatic resuscitation: does the emperor have no clothes? J Trauma Acute Care Surg 2011; 70: 97–102.
12. , , , et al. Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1: 2. J Trauma Acute Care Surg 2011; 70: 90–5.
13. , , , et al. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma. Transfusion 2011; 51: 1925–32.
14. , , , et al. Prevalence of survivor bias in observational studies on fresh frozen plasma: erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012; 116: 716–28.
15. , . Complications of massive transfusion. Chest 2010; 137: 209–20.
16. , , , . Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt) 2004; 5: 395–404.
17. , , . Innate immune dysfunction in trauma patients: from pathophysiology to treatment. Anesthesiology 2012; 117: 411–16.
18. , , , et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104–7.
19. , , , . Injury, sepsis, and the regulation of Toll-like receptor responses. J Leukoc Biol 2004; 75: 400–7.
20. , . The immune response to surgery and trauma: Implications for treatment. J Trauma Acute Care Surg 2012; 73: 801–8.
21. , , , . Long-term-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol 2001; 70: 30–8.
22. , , , et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005; 288: L958–65.
23. , , , et al. Early vasopressor use in critical injury is associated with mortality independent from volume status. J Trauma Acute Care Surg 2011; 71: 565–70.
24. , , , et al. Early use of vasopressors after injury: caution before constriction. J Trauma Acute Care Surg 2008; 64: 9–14.
25. , , , et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23–32.
26. . Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial. BMJ 2011; 343: d3795.
27. , , , . Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147: 113–19.
28. , , , et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology 2011; 114: 862–71.
29. , , , et al. Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. Anesthesiology 2011; 114: 856–61.
30. , , . Preventing cardiac arrest during hemorrhagic shock with vasopressin. Crit Care Med 2008; 36 (11 Suppl): S474–80.
31. , , . Vasopressin deficiency in the syndrome of irreversible shock. J Trauma Acute Care Surg 2003; 54 (5 Suppl): S149–54.
32. , , , et al. Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature. Am J Cardiovasc Drugs 2006; 6: 51–68.
33. , , , et al. Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg 2004; 98: 1759–66.
34. , , , et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 2003; 31: 1160–5.
35. , , , et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226–9.
36. , , , et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist 2005; 54: 220–4.
37. , . Vasopressin in hemorrhagic shock. Anesth Analg 2005; 101: 833–4.
38. , , , . Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth 2005; 19: 170–3.
39. , , , et al. [Vasopressin for therapy of persistent traumatic hemorrhagic shock: The VITRIS.at study]. Anaesthesist 2007; 56: 145–8.
40. , , . Developing alternative strategies for the treatment of traumatic haemorrhagic shock. Curr Opin Crit Care 2008; 14: 247–53.
41. , , , et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S121–7.
42. , , , et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2011; 25: 804–10.
43. , , , et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201–5.
44. , , , et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–85.
45. , , , , . Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003; 53: 34–8.
46. , , , et al. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 2011; 212: 87–95.
47. , , , et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma Acute Care Surg 2004; 57: 709–18; discussion 18–19.
48. , , , et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma Acute Care Surg 2008; 64: 286–93.
49. , , , et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma Acute Care Surg 2005; 59: 8–15.
50. , , , et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital.J Trauma Acute Care Surg 2008; 64 (2 Suppl): S79–85.
51. , , , et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy–a porcine model. Br J Anaesth 2006; 97: 460–7.
52. . The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 (Suppl 1): 91S–5S.
53. , , , et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost 2011; 9: 729–37.
54. , , , et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331: 1105–9.
55. , , . Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma Acute Care Surg 2002; 52: 1141–6.
56. , , . Base excess: a review. J Trauma Acute Care Surg 2012; 73: 27–32.
57. , , , , . Admission base deficit predicts transfusion requirements and risk of complications. J Trauma Acute Care Surg 1996; 41: 769–74.
58. , , . Base deficit is superior to pH in evaluating clearance of acidosis after traumatic shock. J Trauma 1998; 44: 114–18.
59. , , , , , , et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology 2012; 117: 1276–88.
60. , , , et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma Acute Care Surg 2011; 71: 407–14.
61. , , , et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256: 476–86.
62. , , , . TEG(R) and ROTEM(R) in trauma: similar test but different results? World J Emerg Surg 2012; 7 (Suppl 1): S3.